Health news
A web-based survey found that many people with bipolar disorder (BD) used commercial smartphone applications for BD self-management. These findings were published in International Journal of Bipolar Disorders. This study recruited individuals with BD via…
The Food and Drug Administration (FDA) has approved Igalmi (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Igalmi is an orally dissolving thin…
Use of a clinical decision support system was linked to significant reductions in cardiovascular disease risk among patients with schizophrenia, schizoaffective disorder, and bipolar disorder, according to research published in JAMA Network Open. The system…
The Food and Drug Administration (FDA) has approved Caplyta (lumateperone) for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate.…
Lybalvi® (olanzapine and samidorphan) is now available for the treatment of schizophrenia in adults and for bipolar I disorder in adults for acute treatment of manic or mixed episodes as monotherapy and as an adjunct…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021